bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.
bluebird bio, Inc. (the “Company” or “bluebird”) will be conducting meetings with investors attending the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California beginning on January 7, 2019.As part of these meetings, the Company will present the slides furnished to this Current Report as Exhibit 99.1, which is incorporated herein by reference.
The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01Other Events.
On January 7, 2019, bluebird issued a press release announcing that bluebird entered into a license agreement with Inhibrx, Inc. for the research, development and commercialization of cell therapy products for the treatment of cancer.
The full text of bluebird’s press release regarding this announcement is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
bluebird bio, Inc. Exhibit
EX-99.1 2 blue-ex991_51.htm EX-99.1 blue-ex991_51.pptx.htm Making Hope A Reality – bluebird style January 2019 Exhibit 99.1 These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,…
To view the full exhibit click here
About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
